Aoxing Pharmaceutical Company, Inc. (AOXG) Stock Price & Analysis
Aoxing Pharmaceutical Company, Inc. (AOXG) — price $0.0023 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Aoxing Pharmaceutical Company, Inc. · AOXG
Aoxing Pharmaceutical Company, Inc. focuses on the research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products in China. The company's key products include pain relief capsules, herbal supplements, and synthetic narcotic analgesics.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0023 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0011 – $0.0074 | |
| Shares traded on the day | 22.9K |
Price & events
Other perspectives
Council score for Aoxing Pharmaceutical Company (AOXG): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Aoxing Pharmaceutical Company (AOXG), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aoxing Pharmaceutical Company, Inc. (AOXG) is the company analyzed here. It employs 346 people and is led by Zhenjiang Yue. In Q4 FY2026 it reported revenue of $2,884 and net income of -$11,686.
What do the latest results show for Aoxing Pharmaceutical Company (AOXG)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $2,884.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $2,884 | -$11,686 | $0.00 (diluted) |
| Q3 FY2026 | $11,295 | $1,947 | $0.00 (diluted) |
| Q2 FY2026 | $17,212 | -$11,201 | $0.00 (diluted) |
| Q1 FY2026 | $2,080 | -$2,438 | $0.00 (diluted) |
What are the financial strengths and risks for Aoxing Pharmaceutical Company (AOXG)?
Short answer · as of
The distress and quality screens read Piotroski F 2. Trailing ratios: ROA -18.6% · current ratio 0.96 · earnings yield -2.7% · free-cash-flow yield -11.7%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AOXG in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AOXG in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Aoxing Pharmaceutical Company (AOXG)
These answers are editorial: 1 of these 1 answer is drawn from the AOXG research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for AOXG?
Aoxing Pharmaceutical Company, Inc. faces several key risks, including regulatory hurdles in China, intense competition from both domestic and international pharmaceutical companies, and the potential for product liability claims.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 7 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com